A New Brainstem Atlas Maps the Neurons Behind Cagrilintide's Effects

Amylin receptor agonists like cagrilintide are usually described in research literature by what they do — slow gastric emptying, promote satiety, complement GLP-1 receptor agonism — rather than by which specific neurons carry out that signaling. A study published in Nature Metabolism in mid-2026 closes some of that gap. A multi-institution team spanning the University of Copenhagen, Novo Nordisk, the University of Michigan, and the University of Zurich built a large single-cell transcriptomic atlas of the brainstem to trace cagrilintide’s action down to specific, named neuron populations, and in the process found that its mechanism looks meaningfully different from semaglutide’s.

Why the hindbrain is the focus

The dorsal vagal complex (DVC), a cluster of structures at the base of the brainstem, is one of the best-established sites of appetite-regulating signal integration — it’s where circulating satiety signals and neuronal input from the vagus nerve converge. Amylin and its analogues are known to act partly through calcitonin receptor (Calcr)-expressing neurons in this region, but until this study, the field lacked a detailed, cross-species map of exactly which DVC cell types express that receptor and what they do when cagrilintide binds it.

Building the atlas

The researchers profiled more than 530,000 individual brainstem cells across rats, mice, and macaques, identifying roughly 80 distinct neuronal populations, and used spatial transcriptomics to map how those populations are physically distributed within the rat DVC. That scale and cross-species design matters for research translation — a finding confined to one rodent strain is a much weaker basis for reasoning about human biology than one replicated across three species with a shared cell population.

Two Calcr-expressing populations, two different roles

The atlas pointed to two separate conserved neuron populations that respond to cagrilintide, and the study’s more interesting finding is that they don’t behave the same way. Acute cagrilintide exposure changed gene expression in Calcr/Ramp3 neurons in the area postrema, but when the researchers used chemogenetic tools to directly activate those same neurons, it had no effect on long-term food intake or body weight in rats — a useful reminder that a neuron responding to a compound isn’t the same as that neuron driving the compound’s downstream effect.

The population that did matter was a separate set of Calcr neurons in the nucleus of the solitary tract that also express prolactin-releasing hormone (Prlh). Sustained cagrilintide treatment increased Prlh expression in these cells, and this population is conserved not just across rats and mice but in macaques and, per the researchers’ analysis, humans as well. When the team selectively knocked down Prlh in this neuron population, cagrilintide’s effects on energy balance were largely lost.

A mechanistic split from semaglutide

The detail most relevant to anyone tracking combination therapies is what happened when the researchers ran the same Prlh knockdown against semaglutide: semaglutide’s effects were unaffected. In other words, cagrilintide and semaglutide — despite both being investigated for weight management, and despite being combined in the CagriSema research program — appear to route through distinct hindbrain circuits rather than converging on the same downstream neurons. That’s a mechanistic explanation, at the level of specific cell populations, for why pairing an amylin-pathway compound with a GLP-1-pathway compound is a rational combination-research design rather than simply stacking two drugs that do the same thing through the same wiring.

This is preclinical, circuit-mapping research — single-cell sequencing, spatial transcriptomics, and rodent chemogenetics/knockdown experiments, not a human clinical trial of outcomes. It doesn’t establish anything about dosing or individual response; what it does is give researchers a more precise map of where in the brain to look when studying how amylin receptor agonists produce their effects, and a specific, testable distinction between cagrilintide’s circuitry and semaglutide’s.

Further reading

• Ludwig, M.Q., Coester, B., Gordian, D., et al. (2026). “A cross-species atlas of the dorsal vagal complex reveals neural mediators of the effects of cagrilintide on energy balance.” Nature Metabolism, 8(6), 1350–1367. pubmed.ncbi.nlm.nih.gov/42260119 · doi.org/10.1038/s42255-026-01539-3